What is PE 22-28 | 10MG

PE 22-28 | 10MG is a synthetic peptide derivative studied in research for its profound antidepressant properties and action on the central nervous system. It is intended exclusively for research use.

Regarding its chemical identity, PE has a molecular formula of C36H57N11O9 and a molecular weight of 787.9 g/mol. Its reported canonical sequence is Gly-Val-Tyr-Ala-Trp-Ser-Met. A confirmed CAS number is not available in open primary reference sources and is therefore omitted.

Its synonyms include PE.

Product for research use.

Mechanism of action of PE

PE 22-28 functions as a highly specific agonist of the TREK-1 (TWIK-related K+ channel 1) potassium channel. By binding to and modulating these channels in the brain, it alters neuronal excitability, leading to rapid and sustained antidepressant and anxiolytic effects.

Pharmacokinetics and pharmacodynamics of PE

Designed to cross the blood-brain barrier effectively, PE 22-28 has a relatively rapid onset of action compared to traditional SSRIs. Its systemic half-life is moderate, but its specific targeting of potassium channels provides long-lasting downstream neurotransmitter modulation.

Scientific evidence on PE

The available evidence on PE is preliminary and largely inconclusive, and should be interpreted with caution. The literature describes it as having been investigated for multiple indications in preclinical models.

Investigated in preclinical models of severe depression and stress-induced behavioral despair. Early evidence suggests it may provide an alternative pathway for rapid-acting antidepressant effects without the latency period typical of serotonin-based drugs.

PE applications in research

Ideal for (research context):
– In vitro and preclinical studies of its specific receptor pathways.
– Investigation of tissue repair, cell proliferation, and functional restoration in laboratory models.
– Comparative work with related peptides.

Not applicable for:
– clinical, diagnostic or therapeutic use.
– Any administration to humans or animals outside of an authorized research protocol.

Product for research use.

PE protocols in preclinical studies

The literature consulted does not include numerical doses from studies that can be cited for PE, so no trial schemes or quantities are specified.

The presentations of this product (10MG) refer only to the amount of lyophilized peptide per vial (or volume for liquids) and do not constitute a dosage recommendation. The design of any protocol, including concentrations and working volumes, is the responsibility of the researcher, based on their experimental objectives and the relevant primary literature.

Information provided exclusively for research purposes.

Reconstitution and manipulation of PE

As a general guideline for laboratory handling, lyophilized peptides such as PE are usually reconstituted with bacteriostatic water (sterile water with approximately 0.9% benzyl alcohol).

Add the solvent slowly down the side of the vial, letting it run over the lyophilized powder; avoid injecting the stream directly onto the powder.
Do not shake: gently rotate the vial until completely dissolved.
Adjust the solvent volume according to the desired working concentration, considering the 10MG contents of the vial.

These guidelines are for general technique and do not replace the internal procedures of each laboratory.

PE Stability and Storage

As a standard laboratory handling procedure for peptides:

Freeze-dried (unreconstituted): This is the most stable form. It is best preserved by freezing and protecting it from moisture and light for long-term storage.
Reconstituted: once in solution, the peptide is less stable and must be kept refrigerated, being used within a short period; for extended storage, freezing in aliquots is usually preferred.
Avoid repeated freeze-thaw cycles, as they can degrade the peptide.

Given that the molecule is characterized by rapid enzymatic degradation in biological media, careful cold chain management is especially relevant.

Documented PE security profile

The documented safety information in open sources for PE is limited and should be interpreted with caution, also considering that it is research material and not for clinical use.

As a novel neuromodulator, its long-term safety profile is largely unverified. Theoretical risks include alterations in cardiac or neural potassium channel dynamics, though it appears highly selective for TREK-1 in preliminary data.

Formal contraindications and adverse event rates are not available in the consulted literature, so no figures are reported.

PE in a comparative context

Unlike SSRIs (which block serotonin reuptake) or MAOIs (which prevent neurotransmitter breakdown), PE 22-28 targets ion channels directly to alter neuronal firing states. This places it in a unique class of experimental rapid-acting antidepressants.

History and development of PE

Developed as part of a modern wave of neuropharmacology seeking to bypass the traditional monoamine hypothesis of depression. By targeting TREK-1, researchers aimed to create a molecule with the rapid efficacy of ketamine but without the dissociative side effects.